Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy—results of a prospective, multicenter German observational study-Reference-Cited by-同舟云学术

Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy—results of a prospective, multicenter German observational study

Published:2023-04 Issue:2 Volume:8 Page:101201
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Li M.,Mindt S.,Lück A.,Hutzschenreuter U.,Kollendt M.,Lathan B.,Zöller T.,Frank-Gleich S.,Lorentz C.,Lamberti C.,Sick C.,Zingerle M.,Tesch H.,Stein W.,Hebart H.,Stosiek C.,Sandner R.,Fries S.,Burkholder I.,Hofheinz R.-D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper;Wörmann;Oncol Res Treat,2020

2. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommendations for 5-fluorouracil therapy;Beumer;Clin Pharmacol Ther,2019

3. Therapeutic drug monitoring of 5-fluorouracil;Lee;Cancer Chemother Pharmacol,2016

4. Individual 5-fluorouracil dose adjustment via pharmacokinetic monitoring versus conventional body-area-surface method: a meta-analysis;Yang;Ther Drug Monit,2016

5. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer;Gamelin;J Clin Oncol,2008

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Special Issue “Latest Advances in Nanomedicine Strategies for Different Diseases”;International Journal of Molecular Sciences;2024-05-27

2. Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists;Internal Medicine Journal;2024-05-20

3. Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors;Pharmacology Research & Perspectives;2024-03

4. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?;Frontiers in Pharmacology;2023-05-15